Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.
Explore this paper's citation graph
Summary
In the first-line treatment of advanced NSCLC, the combination of cetuximab plus cisplatin/vinorelbine demonstrated an acceptable safety profile and the potential to improve activity over cisplarin/vinORElbine alone.
- Type
- article
- Published
- 2008-02-01
- Cited by
- 269
- References
- 37
- Access
- Open access
- OpenAlex
- https://openalex.org/W17947225
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:13121363
Keywords
Humanities, Phoenix, Philosophy, Geography, Archaeology
References
- Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).
- Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
- The EGF receptor - an essential regulator of multiple epidermal functions.
- Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
- Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
- Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
- Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
- Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.
- Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non–Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor
- Monoclonal antibodies to target epidermal growth factor receptor–positive tumors
- Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials.
- Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
- Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.
- Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
- Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.
- Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
- Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage.
- Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
- Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
- Erlotinib in previously treated non-small-cell lung cancer.
Cited by
- Analyzing the Impact of EGFR-induced c-Met Phosphorylation in Non-Small Cell Lung Cancer
- Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.
- Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents.
- Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787
- Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
- Correlation between the severity of cetuximab-induced skin rash and clinical outcome for head and neck cancer patients: The XXXX experience
- Efficacy of icotinib in advanced lung squamous cell carcinoma
- Unmet Needs in the Treatment of Metastatic Non-small-cell Lung Cancer
- A Translational Approach to Lung Cancer Research
- Impact of genetic markers on treatment of non-small cell lung cancer.
- Traitement des cancers bronchiques non à petites cellules: Maladies avancées (métastatiques). Les recommandations de pratique clinique de l'European Lung Cancer Working Party
- ANGPTL2/LILRB2 signaling promotes the propagation of lung cancer cells
- Cáncer de pulmón de célula no pequeña metastásico
- Targeted therapy: An evolving world of lung cancer
- Pharmacotherapy Update: Vinorelbine in the Treatment of Non-small-cell Lung Cancer
- First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
- The promise of anti-ErbB3 monoclonals as new cancer therapeutics
- Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.
- Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies
- Identificación y análisis funcional de nuevos oncogenes amplificados en cáncer de pulmón
Related papers
No related papers recorded.